Know Cancer

forgot password

A Phase I Trial of Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Phase 1
18 Years
Open (Enrolling)

Thank you

Trial Information

A Phase I Trial of Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

- There are two phases to this research study, Induction Phase and Maintenance Phase.

- Induction Phase: Participants will receive ipilimumab by an infusion into a vein or
central line at weeks 1, 4, 7 and 10 for a total of 4 infusions. Bevacizumab is also
given as an infusion into a vein or central line at weeks 1, 4, 7 and 10 along with
ipilimumab and then every 3 weeks by itself. During all cycles of study therapy, the
participant will have a physical exam on the first day and undergo blood tests at every
study visit. At weeks 1, 4, 7, 10 and 12 a urine sample will be obtained for analysis.

- Chest, abdomen and pelvic CT scans will be performed at week 12. If the scans at week
12 show that the participants cancer has remained stable or decreased, they will be
asked to have repeat CT scans in three months.

- Positron Emission Tomography (PET) scans will be done at week 8 and week 16.

- Maintenance Phase: If the scans performed at week 12 show the cancer has improved or
stayed the same, then the participant will continue to receive bevacizumab every three
weeks and undergo a CT scan every 3 months. Also, every 3 months the participant may
be eligible to receive additional doses of ipilimumab in addition to the bevacizumab.

Inclusion Criteria:

- Measurable unresectable Stage III or Stage IV melanoma

- ECOG Performance Status 0 or 1

- 4 weeks or greater since treatment

- Must have recovered from any acute toxicity associated with prior therapy

- Life expectancy of greater than 12 weeks

- 18 years of age or older

- Laboratory values as outlined in protocol

- Negative screening tests for HIV, active Hepatitis B and Hepatitis C

- Patients who received prior therapy with anthracyclines should have a baseline MUGA
or echo with a normal ejection fraction

Exclusion Criteria:

- CNS metastases

- Pregnant or nursing women

- Prior therapy with bevacizumab or ipilimumab

- Active infection

- Autoimmune disease: Patients with a history of inflammatory bowel disease are
excluded from this study as are patients with a history of symptomatic autoimmune

- Any other malignancy from which the patient has been disease-free for less than 5
years, with the exception of adequately treated and cured basal or squamous cell skin
cancer, superficial bladder cancer or carcinoma in situ of the cervix

- Any underlying medical condition which, in the principal investigator's opinion, will
make the administration of study drug hazardous or obscure the interpretation of
adverse events

- Any concurrent medical condition requiring the use of systemic steroids

- Inadequately controlled hypertension

- Any prior history of hypertensive crisis or hypertensive encephalopathy

- NYHA Grade II or greater congestive heart failure

- History of myocardial infarction or unstable angina within 6 months prior to study

- History of stroke of transient ischemic attack within 6 months prior to study

- Significant known vascular disease

- Symptomatic peripheral vascular disease

- Evidence of bleeding diathesis or coagulopathy

- Major surgical procedure or significant traumatic injury within 28 days prior to
study enrollment

- Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to study enrollment

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to study enrollment

- Serious, non-healing wound, ulcer or bone fracture

- Proteinuria at screening

- Known hypersensitivity to any component of bevacizumab

- History of hemoptysis within 3 months prior to study enrollment

- Current, ongoing treatment with full-dose warfarin or its equivalent

- Current or recent (within 10 days of enrollment) use of aspirin (>325mg/day) or
chronic use of other NSAIDs

- Medications that inhibit platelet function

- Known involvement of melanoma within gastrointestinal tract

- Ulcerated skin lesions

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the safety, tolerability and maximum tolerated dosing for the combination of bevacizumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma

Outcome Time Frame:

3 years

Safety Issue:


Principal Investigator

F. Stephen Hodi, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dana-Farber Cancer Institute


United States: Food and Drug Administration

Study ID:




Start Date:

February 2009

Completion Date:

Related Keywords:

  • Melanoma
  • bevacizumab
  • ipilimumab
  • unresectable stage III melanoma
  • unresectable stage IV melanoma
  • Melanoma



Beth Israel Deaconess Medical Center Boston, Massachusetts  02215
Dana-Farber Cancer Institute Boston, Massachusetts  02115
Massachusetts General Hospital Boston, Massachusetts  02114-2617